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Abstract
The pathologic diagnosis of cancer is an essential initial step in the management of patients, a great respon-
sibility facing the pathologist. The present review is a critical analysis of current practice. The aim is to
disclose defects, describe diagnostic strategies and outline recent changing trends in the use of diagnosticSpecimen fixation;
Survival;
Guidelines
methods. The importance of recognizing syndromic cancers, interpathologist consultation and interdis-
ciplinary cooperation is emphasized. Twenty advises and guidelines are presented which may hopefully
minimize errors and assure an accurate diagnosis. Recent 5-year survival data of different cancer sites
are presented with a proposed classification into four prognostic categories. Curability from cancer is not
uncommon with modern therapy. It is confirmed by the demonstration of a plateau slope graph between 5
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“Patients  worry  over  the  great  number  of  diseases,  pathologists
worry  over  the  difficulty  to  diagnose  them,  whereas,  clinicians
worry  over  the  scarcity  of  effective  therapy.”
The practice of oncology aims to achieve four goals, namely:
correct diagnosis, effective treatment, adequate follow up and fruit-
ful research. Interdisciplinary cooperation of staff is essential to
accomplish these goals. Diagnosis must precede treatment, since it
determines the line of therapy. It must be rapid and precise. This
great responsibility lies on the pathologist who is expected to type
the disease, as well as, to predict its biologic behavior. In most of
cases, these diagnostic and prognostic challenges are successfully
accomplished, but in few problematic cases, difficulties arise and
errors are inevitable. The following are a group of advises and gen-
eral rules that may help to avoid or minimize diagnostic pitfalls and
assure a complete and accurate final pathology report.
1.  Specimen  identification  and  fixation  are two essential and
immediate steps. Labeling of specimen by the name of patient avoids
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he serious interchange of specimens. Bilateral specimens should be
ubmitted separately with labeling of laterality. Immediate fixation
s essential to preserve both morphology and biology of samples.
he type of fixation varies according to the aim of investigation
Table 1).
“Practice  only  does  not  make  perfection,  only  perfect  practice
makes  perfection”
.  Full  clinical  data  should be available to the pathologist, includ-
ng: age, exact site of specimen, clinical diagnosis, type of operation,
ny previous biopsy or therapy. Thus, without reviewing previous
iopsies, it is difficult to tell if a new mass lesion is a recurrence or
 new primary. In addition, histopathologic studies after therapy are
sually unreliable.
“Pathologic  reports  without  clinical  data  are  both  impossible
and  dangerous.”
.  Adequacy  of  a  biopsy  is essential for proper pathologic eval-
ation. For tissue needle biopsy, the WHO recommends multiple
nd hosting by Elsevier B.V. This is an open access article under the CC
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Table  1  Fixation of specimens.
Method Fixative
Routine pathology 10% formalin
Electron microscopy 2.5% glutaraldehyde
Cytology 90% ethyl alcohol or air dryness
Biologic studies Deep freezing (−20 ◦C to −80 ◦C)
Frozen section
Tissue culture
Fresh unfixed
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noma are excluded (by S-100, desmin and cytokeratin negativity).Karyotyping
Flow cytometry
ores not less than 14 mm long, a condition rarely encountered in
ractice. There are several causes of inadequate sample, includ-
ng: scanty material (<1 mm), non-representative tissue, necrotic,
rushed, cauterized or autolyzed samples. In such cases, rebiopsy
f adequate material should be requested.
“The  best  way  to  escape  from  a  problem  is  to  solve  it.”
.  Gross  data  of  resected  cancer  specimens  must include the
ollowing: (a) presence of any cutaneous surgical wound denot-
ng previous lumpectomy, (b) longest diameter (single or multiple
umors), (c) invasion of muscle layer (gut, bladder or myometrium),
d) if capsule of the organ is intact or penetrated by tumor (in thyroid,
idney and ovary), (e) number and size of regional lymph nodes and
f) longest and shortest clearance of normal tissue around the tumor
n cm. Tissue for surgical margin evaluation should be taken from
he shortest clearance by blocks parallel or perpendicular to the sur-
ical margin (Fig. 1). A clearance of 1 cm is satisfactory for most
ancers, but a larger distance (2–3 cm) is needed in melanoma.
.  Size  of  sarcomas  can help to assess the expected biologic behav-
or. Soft tissue sarcomas usually present as deep bulky masses
>5 mm). Similarly, cartilaginous tumors >5 cm are usually malig-
ant. It is wise not to diagnose a sarcoma <2 cm. Exception to
his rule is sarcomas of the skin which may be <1 cm but behave
Figure  1  Tissue clearance and selection of sUro-Oncology
alignant (e.g. Kaposi sarcoma, primary cutaneous lymphomas and
ermatofibrosarcoma).
.  The  triad  foundation  for  diagnosis.  In the nervous and skeletal
ystems, tumor types are numerous and show special age distribu-
ion. Imaging is the only way to gain information on their gross
eatures. For these reasons, an accurate pathologic diagnosis is only
ossible after considering these three types of information, namely:
he age, radiography or MRI and histology.
.  Diagnosis  by  probability.  In the search for a diagnosis, it is wise
o consider common rather than rare diseases. Thus, an axillary
ymphadenopathy in a female usually represents metastasis from
reast, but in males it is commonly a lymphoma or melanoma.
“a  rare  presentation  of  a  common  disease  is  more  common  than
a  common  presentation  of  a  rare  disease.”
.  The  importance  of  consultation.  A difficult case confronting a
eginner pathologist will end up by misdiagnosis and mismanage-
ent. Consultation with a senior pathologist will help to avoid this
itfall.
“What  the  mind  does  not  know,  the  eye  can  not  see”
“Good  judgment  comes  from  experience,  and  experience  comes
from  bad  judgment”
.  Diagnosis  by  exclusion.  In difficult cases, differential diagno-
is must be considered and a Sherlock Holmes detective strategy
dopted. For example, in a spindle cell malignancy, fibrosarcoma is
he ultimate diagnosis if neural, myogenic and sarcomatoid carci-“When  you  have  excluded  all  the  impossible,  whatever  remains
must  be  the  truth.”
urgical margins from excised specimens.
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10.  The  uncertain  behavior.  Some tumors are difficult to predict
their biologic behavior from their histologic picture (e.g. neuroen-
docrine tumors and gastrointestinal stromal tumors (GIST)). In such
cases, prognostic markers may help (e.g. Ki-67 proliferation index,
the presence of gene mutation). The following Chinese proverb
applies on those who make a definite decision on the uncertain.
“To  be  uncertain  is  to  be  uncomfortable,  but,  to  be  certain  is  to
be  ridiculous.”
11.  The  undifferentiated/unclassified  tumor  type.  About 10% of
tumors are difficult to type even with the use of immunohistochem-
istry. Pathologists, however, are generally ashamed to use this term.
Such tumors are given names descriptive to their cytomorphology
(e.g. spindle, round, epithelioid or pleomorphic cells).
12.  The  stem  cell  component.  All malignant tumors have a stem
cell population, but are rather difficult to visualize. There is no spe-
cific marker for stem cells (except for CD34 in hematolymphoid
malignancies). Recently, some morphologic features are described
to suggest stem cell component in a tumor, namely: a population
of uniform mall round cells, scanty cytoplasm, marker negativity
and associated fibrosis. Ki-67 nuclear labeling rate is a measure of
cycling stem cells (growth fraction).
13.  Limitations  of  frozen  section.  In sclerosing epithelial lesions
of breast, as well as, intraductal papillary tumors, it is difficult to
distinguish benign from malignant lesions by frozen section. In such
cases, the definitive diagnosis should be deferred to paraffin section
studies. This will also allow the use of S-100 marker to identify
myoepithelial cells in the lesion, thus confirming its benign nature.
The age of the patient must also be taken into consideration. Thus,
in young patients (<20 years) all suspicious breast masses should
be deferred to paraffin section evaluation. It is noteworthy also, that
frozen section is inapplicable for bone tumors and small impalpable
masses. Moreover the results of frozen section examinations for
surgical margins are rather inaccurate. Currently, tissue core needle
biopsy is replacing frozen section, with high sensitivity (98%) and
specificity (99%). Moreover it allows informed consent of patient
and is applicable in nonpalpable tumors when guided by imaging.
14.  Limitations  of  immunophenotyping.  Immunohistochemistry
has its handicaps (e.g. false negativity, co-expression and aberrant
expression), hence, in some cases, results of markers are ambiguous.
Accordingly, whenever a disagreement exists between immunophe-
notyping and morphologic typing of tumors, the latter should take
the upper hand and typing based on histomorphologic features.
Contrary to immunophenotyping, electron microscopic studies are
highly specific and helpful in the diagnosis of some difficult cases
(e.g. melanoma, Langerhans histiocytosis, neuroendocrine tumors
and undifferentiated cancer).
15.  Molecular  genetic  tests  (FISH and PCR technologies) are
valuable for the following selected cases: (a) genotyping and clas-
sification of hematolymphoid malignancies and solid tumors, (b)
detection of minimal residual disease, (c) confirm syndromic can-
cer by identifying germline mutations, (d) detection of oncogenes
important for targeted therapy (e.g. BCR-ABL1 mutation in CML,
PML-PARA fusion gene in premyelocytic leukemia, C-Kit in GIST,
Her-2 in breast carcinoma, EGFR in non-small cell lung cancer and
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lioblastoma multiforme, VEGF as well as FLI-3 in melanoma and
e) predict prognosis (e.g. N-myc amplification in neuroblastoma).
6.  Genomic  tests.  The recent microarray technology allows the
nalysis of thousands of genes from a single tumor sample. More-
ver, it is also possible through next generation sequencing to
nalyze the entire genome. In these methods, the strategy is to iden-
ify the entire mutation spectrum of a given tumor and to develop
pecific drugs for its treatment (personalized medicine through phar-
acogenetic approach). However, cost-benefit analysis must be
onsidered in such cases. The high cost of this technology prohibits
ts routine or even research use. Other less expensive techniques
ay be used to accomplish the same goal.
7.  Syndromic  cancer, which contributes about 10% of practice,
s suspected in the following clinical settings: (a) adult malig-
ancies arising in young patients (colonic or breast carcinoma in
 child), (b) bilateral or multiple cancers, whether endocrine or
on-endocrine (e.g. medullary thyroid carcinoma and pheochro-
ocytoma in MEN-2B syndrome, breast-ovary BRCA syndrome,
olon-endometrium double cancers in Lynch syndrome and basal,
quamous and melanoma multiple cancers in xeroderma pigmento-
um). (c) Family history of the same cancer, (d) unusual presentation
f cancer (e.g. breast cancer affecting males). (e) Some cutaneous
anifestations are also reliable indication of syndromic cancers.
t is important to recognize syndromic cancer for three main rea-
ons, namely (a) genetic counseling of all family members with
areful follow up, (b) in case of multiple tumors, the priority of
anagement is given to the more aggressive tumor, and (c) in case
f cancers resulting from defect in DNA repair or hypersensitivity
o irradiation, radiotherapy is contraindicated (e.g. BRCA-related
reast cancer, xeroderma pigmentosum, Lynch syndrome and ataxia
elangiectasia)
8.  The  final  pathology  report.  In case of radical surgical resection
pecimens for cancer, the report must include the following infor-
ation: (a) histologic type of cancer, (b) the grade of malignancy,
c) the stage of cancer (preferably TNM if applicable, or other stag-
ng classification as FIGO, lymphoma or pediatric systems), (d)
he status of regional lymph nodes (indicating the number of pos-
tive lymph nodes and total nodes examined), (e) presence of any
ymphangio-invasion, (f) the status of surgical margin (negative,
lose or positive for malignancy) and (g) the grade of therapy effect
n case of neoadjuvant chemo or radiotherapy. Three grades may be
pplied, namely: no effect with viable tumor cells predominating,
artial effect with estimation of necrotic tumor area (%) or complete
herapy effect with massive tumor necrosis, fibrosis and no viable
eoplastic cells.
“Perfection  is  achieved  when  there  is  nothing  left  to  add  or  to
take  away.”
9. Survival  of  cancer  patients. By studying historical reports
rom USA, a significant increase in 5 year survival of cancer
atients during the 20th century (from 0.0% to over 60%). Thanks
o the break through discoveries of effective therapeutic modalities,
amely: radical surgery, advanced linear acceleration, combination
hemotherapy, bone marrow transplantation and targeted therapy. In
 recent report of SEER data a 5 year survival of 67% was reported in
atients treated by recent protocols. We propose to classify survival
ata into four categories in descending order of survival intervals
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Table  2  Five-year survival by cancer site.
Prognostic category
(survival interval)
Site (survival %)
I. Most favorable
(80–100%)
Prostate (99%)
Thyroid (98%)
Testis (96%)
Melanoma (92%)
Breast (89%)
Hodgkin (86%)
CLL (82%)
Endometrial
(82%)
II. Favorable
(50–80%)
Bladder (77%)
Kidney (73%)
NHL (70%)
Cervix (68%)
ALL (68%)
Colorectal (65%)
CML (63%)
Larynx (61%)
III. Unfavorable
(20–50%)
Myeloma (47%)
Ovary (46%)
Brain (33%)
Stomach (29%)
AML (26%)
IV. Most unfavorable
(0–20%)
Esophagus (18%)
Liver (7%)
Pancreas (7%)
SEER data, USA (2015) [1].
Abbreviations: CLL: chronic lymphocytic leukemia. NHL: non-Hodgkin
lymphoma; ALL: acute lymphatic leukemia; CML: chronic myeloid
leukemia; AML: acute myeloid leukemia.
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E-mail address: dr.nbolk@gmail.comigure  2  Long-term Edward Taft slopegraphs for cancer patients.
urable cases has a plateau curve (solid line), whereas, incurable
atients show a declining curve (dashed lines).
Table 2). In addition, 5 types of cancer have zero percent 5 year sur-
ival due to the present lack of effective treatment, survival time is
nly 4–20 months. This fatal group include: glioblastoma, small cell
ung cancer, anaplastic thyroid carcinoma, brain lymphoma (NHL)
nd acute adult T-cell leukemia/lymphoma. It is noteworthy, how-
ver, that survival statistics are just a rough estimate of groups of
atient but never precise in an individual patient.
“Patient  and  their  families  may  forgive  a  wrong  diagnosis,  but
not  a  wrong  prognosis”
0.  Curability  of  cancer. There are three unhappy outcomes after
ancer therapy, namely: locoregional recurrence, distant metastasis
nd iatrogenic new primary. These events usually develop over a
eriod of 20 years after therapy. A patient is considered cured if
e survives 20 years after treatment and did not develop any of
R
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hese mishaps. Thus it is possible to evaluate curability by long-term
urvival analysis and studying the slopegraphs during the period of
–20 years [2]. Patient with plateau shaped curve are considered
ured (Fig. 2). A classic example of potentially curable cancer is
urkitt lymphoma.
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